Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α

Paul G Braunschweiger, Steven A. Jones, Candace S. Johnson, Philip Furmanski

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The time- and dose-dependent effects of recombinant human interleukin 1α (IL-1α) on the antitumor activity of mitomycin C (MMC) and porfiromycin (PORF) were studied in RIF-1 and Panc02 solid tumor model systems. IL-1α produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo. IL-1α chemosensitization was highly schedule dependent, and the most efficacious schedules produced dose-modifying factors of 3.6 and 5.1 for MMC and PORF, respectively. More than additive clonogenic cell kill after IL-1α-chemotherapy combinations reflected increased cellular sensitivity to MMC and PORF. The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may have also potentiated the microvascular injury and ischemia produced by IL-1α. Dexamethasone inhibited and ketoconazole, an inhibitor of corticosterone biosynthesis, enhanced IL-1α-mediated chemosensitization in these models. IL-1α mediated chemosensitization to MMC, and PORF was also demonstrated by tumor growth inhibition in the RIF-1 model and increased survival of mice in the spontaneously metastasizing Panc02 system. Chemosensitization of bone marrow spleen colony-forming units was not seen. IL-1α (1000 units/ml) had no effect on MMC and PORF cytotoxicity in RIF-1 and PORF cell lines in vitro. The results indicate that the tumor-specific IL-1α-induced pathophysiologies can sensitize solid tumors to agents which are preferentially activated, retained, and cytotoxic to cells under hypoxic conditions. Our results suggest that strategies combining bioreductively activated hypoxic cell cytotoxins and biological agents might offer efficacious alternatives or adjuvants to conventional combination approaches.

Original languageEnglish
Pages (from-to)5454-5460
Number of pages7
JournalCancer Research
Volume51
Issue number20
StatePublished - Oct 15 1991

Fingerprint

Porfiromycin
Mitomycin
Interleukin-1
Neoplasms
Appointments and Schedules
Ketoconazole
Cytotoxins
Biological Factors
Corticosterone
Combination Drug Therapy
Dexamethasone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Braunschweiger, P. G., Jones, S. A., Johnson, C. S., & Furmanski, P. (1991). Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α. Cancer Research, 51(20), 5454-5460.

Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α. / Braunschweiger, Paul G; Jones, Steven A.; Johnson, Candace S.; Furmanski, Philip.

In: Cancer Research, Vol. 51, No. 20, 15.10.1991, p. 5454-5460.

Research output: Contribution to journalArticle

Braunschweiger, PG, Jones, SA, Johnson, CS & Furmanski, P 1991, 'Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α', Cancer Research, vol. 51, no. 20, pp. 5454-5460.
Braunschweiger, Paul G ; Jones, Steven A. ; Johnson, Candace S. ; Furmanski, Philip. / Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α. In: Cancer Research. 1991 ; Vol. 51, No. 20. pp. 5454-5460.
@article{4147cbafa27243c58b8d3474b9be7326,
title = "Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α",
abstract = "The time- and dose-dependent effects of recombinant human interleukin 1α (IL-1α) on the antitumor activity of mitomycin C (MMC) and porfiromycin (PORF) were studied in RIF-1 and Panc02 solid tumor model systems. IL-1α produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo. IL-1α chemosensitization was highly schedule dependent, and the most efficacious schedules produced dose-modifying factors of 3.6 and 5.1 for MMC and PORF, respectively. More than additive clonogenic cell kill after IL-1α-chemotherapy combinations reflected increased cellular sensitivity to MMC and PORF. The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may have also potentiated the microvascular injury and ischemia produced by IL-1α. Dexamethasone inhibited and ketoconazole, an inhibitor of corticosterone biosynthesis, enhanced IL-1α-mediated chemosensitization in these models. IL-1α mediated chemosensitization to MMC, and PORF was also demonstrated by tumor growth inhibition in the RIF-1 model and increased survival of mice in the spontaneously metastasizing Panc02 system. Chemosensitization of bone marrow spleen colony-forming units was not seen. IL-1α (1000 units/ml) had no effect on MMC and PORF cytotoxicity in RIF-1 and PORF cell lines in vitro. The results indicate that the tumor-specific IL-1α-induced pathophysiologies can sensitize solid tumors to agents which are preferentially activated, retained, and cytotoxic to cells under hypoxic conditions. Our results suggest that strategies combining bioreductively activated hypoxic cell cytotoxins and biological agents might offer efficacious alternatives or adjuvants to conventional combination approaches.",
author = "Braunschweiger, {Paul G} and Jones, {Steven A.} and Johnson, {Candace S.} and Philip Furmanski",
year = "1991",
month = "10",
day = "15",
language = "English",
volume = "51",
pages = "5454--5460",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1α

AU - Braunschweiger, Paul G

AU - Jones, Steven A.

AU - Johnson, Candace S.

AU - Furmanski, Philip

PY - 1991/10/15

Y1 - 1991/10/15

N2 - The time- and dose-dependent effects of recombinant human interleukin 1α (IL-1α) on the antitumor activity of mitomycin C (MMC) and porfiromycin (PORF) were studied in RIF-1 and Panc02 solid tumor model systems. IL-1α produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo. IL-1α chemosensitization was highly schedule dependent, and the most efficacious schedules produced dose-modifying factors of 3.6 and 5.1 for MMC and PORF, respectively. More than additive clonogenic cell kill after IL-1α-chemotherapy combinations reflected increased cellular sensitivity to MMC and PORF. The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may have also potentiated the microvascular injury and ischemia produced by IL-1α. Dexamethasone inhibited and ketoconazole, an inhibitor of corticosterone biosynthesis, enhanced IL-1α-mediated chemosensitization in these models. IL-1α mediated chemosensitization to MMC, and PORF was also demonstrated by tumor growth inhibition in the RIF-1 model and increased survival of mice in the spontaneously metastasizing Panc02 system. Chemosensitization of bone marrow spleen colony-forming units was not seen. IL-1α (1000 units/ml) had no effect on MMC and PORF cytotoxicity in RIF-1 and PORF cell lines in vitro. The results indicate that the tumor-specific IL-1α-induced pathophysiologies can sensitize solid tumors to agents which are preferentially activated, retained, and cytotoxic to cells under hypoxic conditions. Our results suggest that strategies combining bioreductively activated hypoxic cell cytotoxins and biological agents might offer efficacious alternatives or adjuvants to conventional combination approaches.

AB - The time- and dose-dependent effects of recombinant human interleukin 1α (IL-1α) on the antitumor activity of mitomycin C (MMC) and porfiromycin (PORF) were studied in RIF-1 and Panc02 solid tumor model systems. IL-1α produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo. IL-1α chemosensitization was highly schedule dependent, and the most efficacious schedules produced dose-modifying factors of 3.6 and 5.1 for MMC and PORF, respectively. More than additive clonogenic cell kill after IL-1α-chemotherapy combinations reflected increased cellular sensitivity to MMC and PORF. The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may have also potentiated the microvascular injury and ischemia produced by IL-1α. Dexamethasone inhibited and ketoconazole, an inhibitor of corticosterone biosynthesis, enhanced IL-1α-mediated chemosensitization in these models. IL-1α mediated chemosensitization to MMC, and PORF was also demonstrated by tumor growth inhibition in the RIF-1 model and increased survival of mice in the spontaneously metastasizing Panc02 system. Chemosensitization of bone marrow spleen colony-forming units was not seen. IL-1α (1000 units/ml) had no effect on MMC and PORF cytotoxicity in RIF-1 and PORF cell lines in vitro. The results indicate that the tumor-specific IL-1α-induced pathophysiologies can sensitize solid tumors to agents which are preferentially activated, retained, and cytotoxic to cells under hypoxic conditions. Our results suggest that strategies combining bioreductively activated hypoxic cell cytotoxins and biological agents might offer efficacious alternatives or adjuvants to conventional combination approaches.

UR - http://www.scopus.com/inward/record.url?scp=0025937469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025937469&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 5454

EP - 5460

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -